Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis

Kitayama,Kazumichi; Kawamoto,Teruya; Kawakami,Yohei; Hara,Hitomi; Takemori,Toshiyuki; Fujiwara,Shuichi; Yahiro,Shunsuke; Miyamoto,Tomohiro; Mifune,Yutaka; Hoshino,Yuichi; Kakutani,Kenichiro; Matsumoto,Tomoyuki; Matsushita,Takehiko; Niikura,Takahiro; Kuroda,Ryosuke; Akisue,Toshihiro

doi:10.3892/ijo.2021.5277

Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis

Authors:
- Kazumichi Kitayama
- Teruya Kawamoto
- Yohei Kawakami
- Hitomi Hara
- Toshiyuki Takemori
- Shuichi Fujiwara
- Shunsuke Yahiro
- Tomohiro Miyamoto
- Yutaka Mifune
- Yuichi Hoshino
- Kenichiro Kakutani
- Tomoyuki Matsumoto
- Takehiko Matsushita
- Takahiro Niikura
- Ryosuke Kuroda
- Toshihiro Akisue
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo 650‑0017, Japan
Published online on: October 29, 2021 https://doi.org/10.3892/ijo.2021.5277
Article Number: 97
Copyright: © Kitayama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteolytic bone metastasis leads to skeletal‑related events, resulting in a decline in the patient activities and survival; therefore, it is important to understand the mechanism underlying bone metastasis. Recent studies have suggested that microRNAs (miRNAs or miRs) are involved in osteoclast differentiation and/or osteolytic bone metastasis; however, the roles of miRNAs have not been elucidated. In the present study, the roles of miRNAs in bone destruction caused by breast cancer metastasis were investigated in vitro and in vivo. miR‑16, miR‑133a and miR‑223 were transfected into a human breast cancer cell line, MDA‑MB‑231. The expression of osteolytic factors in conditioned medium (miR‑CM) collected from the culture of transfected cells was assessed. To evaluate the effects of miRNAs on osteoclast differentiation and activities, tartrate‑resistant acid phosphatase (TRAP) staining and bone resorptive assays were performed in osteoclasts following miR‑CM treatment. To create in vivo bone metastasis models for histological and morphometric evaluation, miRNA‑transfected MDA‑MB‑231 cells were transplanted into the proximal tibia of nude mice. Expression of osteolytic factors, including receptor activator for nuclear factor‑κB ligand (RANKL), interleukin (IL)‑1β, IL‑6, parathyroid hormone‑related protein (PTHrP), and tumor necrosis factor (TNF), was increased in miR‑16‑CM, whereas it was decreased in both miR‑133a‑CM and miR‑223‑CM. TRAP staining and bone resorptive assays revealed that osteoclast function and activities were promoted by miR‑16‑CM treatment, whereas they were suppressed by miR‑133a‑CM and miR‑223‑CM. Consistent with in vitro findings, in vivo experiments revealed that the overexpression of miR‑16 increased osteoclast activities and bone destruction in MDA‑MB‑231 cells, whereas the opposite results were observed in both miR‑133a‑ and miR‑223‑transfected MDA‑MB‑231 cells. Our results indicated that miR‑16 promoted osteoclast activities and bone destruction caused by breast cancer metastasis in the bone microenvironment, whereas miR‑133a and miR‑223 suppressed them. These miRNAs could be potential biomarkers and therapeutic targets for breast cancer bone metastasis.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Li Z and Kang Y: Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther. 161:79–96. 2016. View Article : Google Scholar : PubMed/NCBI
3	Cai WL, Huang WD, Li B, Chen TR, Li ZX, Zhao CL, Li HY, Wu YM, Yan WJ and Xiao JR: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol Cancer. 17:92018. View Article : Google Scholar : PubMed/NCBI
4	Coleman RE: Bisphosphonates: Clinical experience. Oncologist. 9(Suppl 4): 14–27. 2004. View Article : Google Scholar : PubMed/NCBI
5	D'Oronzo S, Gregory W, Nicholson S, Chong YK, Brown J and Coleman R: Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. J Bone Oncol. 28:1003672021. View Article : Google Scholar : PubMed/NCBI
6	Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, et al: Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents. Oncologist. 21:508–513. 2016. View Article : Google Scholar : PubMed/NCBI
7	Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer. 55:61–66. 1987. View Article : Google Scholar : PubMed/NCBI
8	Lu X and Kang Y: Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia. 12:153–162. 2007. View Article : Google Scholar : PubMed/NCBI
9	Taube T, Elomaa I, Blomqvist C, Beneton MN and Kanis JA: Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone. 15:161–166. 1994. View Article : Google Scholar : PubMed/NCBI
10	Weidle UH, Birzele F, Kollmorgen G and Rüger R: Molecular mechanisms of bone metastasis. Cancer Genomics Proteomics. 13:1–12. 2016.
11	Siclari VA, Guise TA and Chirgwin JM: Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev. 25:621–633. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sutherland A, Forsyth A, Cong Y, Grant L, Juan TH, Lee JK, Klimowicz A, Petrillo SK, Hu J, Chan A, et al: The role of prolactin in bone metastasis and breast cancer cell-mediated osteoclast differentiation. J Natl Cancer Inst. 108:1082015.
13	Hussein O, Tiedemann K and Komarova SV: Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis. Bone. 48:202–211. 2011. View Article : Google Scholar
14	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
15	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
16	Browne G, Taipaleenmäki H, Stein GS, Stein JL and Lian JB: MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab. 25:320–327. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D and Kang Y: Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 24:542–556. 2013. View Article : Google Scholar : PubMed/NCBI
18	Usmani A, Shoro AA, Shirazi B, Memon Z and Hussain M: MiR-16: A novel hereditary marker in breast cancer and their offspring. J Pak Med Assoc. 67:446–450. 2017.PubMed/NCBI
19	Sui Y, Zhang X, Yang H, Wei W and Wang M: MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1. Oncol Rep. 39:473–482. 2018.
20	Zhang L, Li H, Zang Y and Wang F: NLRP3 inflammasome inactivation driven by miR 223 3p reduces tumor growth and increases anticancer immunity in breast cancer. Mol Med Rep. 19:2180–2188. 2019.PubMed/NCBI
21	Sugatani T and Hruska KA: MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem. 101:996–999. 2007. View Article : Google Scholar : PubMed/NCBI
22	Sugatani T and Hruska KA: Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem. 284:4667–4678. 2009. View Article : Google Scholar :
23	Xu XY, Guo C, Yan YX, Guo Y, Li RX, Song M and Zhang XZ: Differential effects of mechanical strain on osteoclastogenesis and osteoclast-related gene expression in RAW264.7 cells. Mol Med Rep. 6:409–415. 2012.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Modderman WE, Tuinenburg-Bol Raap AC and Nijweide PJ: Tartrate-resistant acid phosphatase is not an exclusive marker for mouse osteoclasts in cell culture. Bone. 12:81–87. 1991. View Article : Google Scholar : PubMed/NCBI
26	Faul F, Erdfelder E, Lang AG and Buchner A: G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 39:175–191. 2007. View Article : Google Scholar : PubMed/NCBI
27	Okada Y, Ueno H, Katagiri M, Oneyama T, Shimomura K, Sakurai S, Mataga I, Moride M and Hasegawa H: Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology. 98:52–59. 2010. View Article : Google Scholar : PubMed/NCBI
28	Mishra S, Tang Y, Wang L, deGraffenried L, Yeh IT, Werner S, Troyer D, Copland JA and Sun LZ: Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. Prostate. 71:1441–1454. 2011. View Article : Google Scholar : PubMed/NCBI
29	Papachristou DJ, Basdra EK and Papavassiliou AG: Bone metastases: Molecular mechanisms and novel therapeutic interventions. Med Res Rev. 32:611–636. 2012. View Article : Google Scholar
30	Kingsley LA, Fournier PG, Chirgwin JM and Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther. 6:2609–2617. 2007. View Article : Google Scholar : PubMed/NCBI
31	Hofbauer LC, Rachner TD, Coleman RE and Jakob F: Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol. 2:500–512. 2014. View Article : Google Scholar : PubMed/NCBI
32	Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2:584–593. 2002. View Article : Google Scholar : PubMed/NCBI
33	Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
34	Roodman GD: Biology of osteoclast activation in cancer. J Clin Oncol. 19:3562–3571. 2001. View Article : Google Scholar : PubMed/NCBI
35	Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140:4451–4458. 1999. View Article : Google Scholar : PubMed/NCBI
36	Tulotta C and Ottewell P: The role of IL-1B in breast cancer bone metastasis. Endocr Relat Cancer. 25:R421–R434. 2018. View Article : Google Scholar : PubMed/NCBI
37	Fili S, Karalaki M and Schaller B: Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer Lett. 283:10–19. 2009. View Article : Google Scholar : PubMed/NCBI
38	Palmqvist P, Persson E, Conaway HH and Lerner UH: IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 169:3353–3362. 2002. View Article : Google Scholar : PubMed/NCBI
39	Sunyer T, Lewis J, Collin-Osdoby P and Osdoby P: Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest. 103:1409–1418. 1999. View Article : Google Scholar : PubMed/NCBI
40	Wu X, Zeng R, Wu S, Zhong J, Yang L and Xu J: Comprehensive expression analysis of miRNA in breast cancer at the miRNA and isomiR levels. Gene. 557:195–200. 2015. View Article : Google Scholar
41	Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66:7390–7394. 2006. View Article : Google Scholar : PubMed/NCBI
42	Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI
43	Chen WS, Leung CM, Pan HW, Hu LY, Li SC, Ho MR and Tsai KW: Silencing of miR-11 and miR-133a2 cluster expression by DNA hypermethylation in colorectal cancer. Oncol Rep. 28:1069–1076. 2012. View Article : Google Scholar : PubMed/NCBI
44	Shi W, Tang T, Li X, Deng S, Li R, Wang Y, Wang Y, Xia T, Zhang Y, Zen K, et al: Methylation-mediated silencing of miR-133a-3p promotes breast cancer cell migration and stemness via miR-133a-3p/MAML1/DNMT3A positive feedback loop. J Exp Clin Cancer Res. 38:4292019. View Article : Google Scholar : PubMed/NCBI
45	Fabris L, Berton S, Citron F, D'Andrea S, Segatto I, Nicoloso MS, Massarut S, Armenia J, Zafarana G, Rossi S, et al: Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene. 35:4914–4926. 2016. View Article : Google Scholar : PubMed/NCBI
46	Wang X, Tong Z and Liu H: MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells. OncoTargets Ther. 12:7675–7684. 2019. View Article : Google Scholar
47	McGuire A, Brown JA and Kerin MJ: Metastatic breast cancer: The potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015. View Article : Google Scholar : PubMed/NCBI
48	Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A and Alajez NM: Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis. 8:e30452017. View Article : Google Scholar : PubMed/NCBI
49	Di Mauro V, Crasto S, Colombo FS, Di Pasquale E and Catalucci D: Wnt signalling mediates miR-133a nuclear re-localization for the transcriptional control of Dnmt3b in cardiac cells. Sci Rep. 9:93202019. View Article : Google Scholar : PubMed/NCBI
50	Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R and Olson EN: microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22:3242–3254. 2008. View Article : Google Scholar : PubMed/NCBI
51	Roffel MP, Bracke KR, Heijink IH and Maes T: miR-223: A key regulator in the innate immune response in asthma and COPD. Front Med (Lausanne). 7:1962020. View Article : Google Scholar
52	Ye D, Zhang T, Lou G and Liu Y: Role of miR-223 in the pathophysiology of liver diseases. Exp Mol Med. 50:1–12. 2018. View Article : Google Scholar
53	Wang M, Xia F, Wei Y and Wei X: Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res. 8:302020. View Article : Google Scholar : PubMed/NCBI
54	Fares J, Fares MY, Khachfe HH, Salhab HA and Fares Y: Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduct Target Ther. 5:282020. View Article : Google Scholar : PubMed/NCBI